POME

JRCT ID: jRCT1040220010

Registered date:23/04/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: esophageal cancer
• Date of first enrollment: 09/09/2022
• Target sample size: 1000
• Study type: Observational

Outcome(s)

• Primary Outcome: To investigate the patterns of treatment in patients who received a histological diagnosis of esophageal cancer (squamous, adenosquamous) who started chemotherapy for metastatic or recurrent esophageal cancer from January 1, 2013 to December 31, 2018.
• Secondary Outcome: OS, clinical course (response rate, recurrence or metastasis, duration) and timings by type of chemotherapy, factors affecting outcomes

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1.Patients diagnosed with metastatic or recurrent esophageal squamous or adenosquamous cancer from January 1, 2013 to December 31, 2018
2. Age: 20 years or older
3. Patients in the above categories (1) to (4) of patients eligible for chemotherapy for esophageal cancer from January 2013 to the end of December 2018 who have received chemotherapy for metastasis or recurrence
4. Patients from whom appropriate consent is obtained (see General Informed Consent)

All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the study.

• Exclude criteria: Patients who were registered in a clinical study at the time of the first chemotherapy treatment for metastatic or recurrent esophageal cancer

Related Information

• Primary Sponsor: Kei Muro
• Source(s) of Monetary Support: MSD K.K., Tokyo, Japan